Trials / Withdrawn
WithdrawnNCT00365443
Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)
Proprietary Information - Exploratory (Non-Confirmatory) Trial
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Female
- Age
- 16 Years – 26 Years
- Healthy volunteers
- Accepted
Summary
This study is to evaluate an investigational vaccine with the following objectives: (1) To demonstrate prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by the HPV types in the study vaccine, (2) To demonstrate that the vaccine is well-tolerated in women, (3) To evaluate vaccine immune responses in women. This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | V502 |
Timeline
- Start date
- 2006-10-01
- First posted
- 2006-08-17
- Last updated
- 2015-06-19
Source: ClinicalTrials.gov record NCT00365443. Inclusion in this directory is not an endorsement.